多重リスク因子介入試験の高血圧患者における腎機能の変化. 人種と治療効果. MRFIT研究グループは,MRFITの研究グループを設立しました
W G Walker1, J D Neaton, J A Cutler
1School of Medicine, Johns Hopkins University, Baltimore, Md.
JAMA
|December 2, 1992
まとめ
高血圧は,特に黒人男性において,腎臓機能の低下に寄与する. 効果的な血圧管理は非黒人の個人に利益をもたらしますが,黒人男性への影響は大きいです.
科学分野:
- ネフロロジーはネフロロジーを用います.
- 心臓病学 心臓病学
- 公衆衛生は公衆衛生である.
背景:
- 軽度から中等度の高血圧は,進行性腎臓機能低下の重要なリスク因子です.
- 高血圧が人種間の腎機能に与える影響の違いを理解することは,標的を絞った介入に不可欠です.
研究 の 目的:
- 軽度から中等度の高血圧が,腎機能の漸進的な低下にどのように寄与するかを評価する.
- これらの貢献を評価するために,多重リスク因子介入試験 (MRFIT) の腎機能データを分析する.
主な方法:
- 5524人の高血圧男性 (463人の黒人,5061人の非黒人) の7年間の追跡期間における相互のクレアチニン傾斜の分析.
- 腎機能の変化に影響を与える要因として,血圧制御,年齢,人種,および出血血圧の評価.
- 特殊介入 (SI) グループと通常のケア (UC) グループ間の結果の比較.
主要な成果:
- 黒人男性では,白人男性と比較して腎機能が著しく低下した (P < .001).
- シストリックおよびダイアストリック血圧の上昇,および高齢化は,より大きな腎機能低下 (P < .001) と関連していました.
- 95mmHg未満のダイアストリック血圧を維持することは,結合グループにおける安定したまたは改善された腎機能と関連していたが,この効果は黒人男性では観察されなかった.
結論:
- 効果的な血圧制御は,非黒人の個体では安定したまたは改善された腎機能と関連しているが,黒人の個体ではそうではない.
- これらの発見は,高血圧の白人男性における腎機能の保全のために,血圧管理の重要性を強調しています.
- 黒人集団における血圧低下と腎機能の変化の複雑な関係を理解するために,さらなる研究が必要である.
関連する概念動画
Factors affecting Blood pressure
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Physiological Factors:
Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
